Trials / Completed
CompletedNCT00092976
Study Evaluating ReFacto® in Hemophilia A Undergoing Major Surgery
A Phase IV Study of the Safety and Efficacy of ReFacto® (Moroctocog Alfa, B-Domain Deleted Recombinant Factor VIII) in Subjects With Hemophilia A Undergoing Major Surgery Monitored Using the Chromogenic Substrate Assay at the Local Laboratory
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 15 (estimated)
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer · Industry
- Sex
- Male
- Age
- 6 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this clinical research study is to evaluate the safety and efficacy of ReFacto in subjects with hemophilia A undergoing major surgery monitored using the chromogenic substrate assay at the local laboratory.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ReFacto |
Timeline
- Start date
- 2003-02-01
- Completion
- 2007-07-01
- First posted
- 2004-09-29
- Last updated
- 2007-12-28
Locations
4 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00092976. Inclusion in this directory is not an endorsement.